Department of Emergency Medicine Archive

From left, Frank Harrell Jr., PhD, Paul Harris, PhD, Wesley Self, MD, James Chappell, MD, PhD, Gordon Bernard, MD, Jana Shirey-Rice, PhD, and Jillian Rhoads, PhD, play key roles in a national effort to advance the understanding and treatment of acute respiratory distress syndrome, pneumonia and sepsis.
May 4, 2023

VUMC to coordinate national effort to reduce ARDS, pneumonia, sepsis

Vanderbilt University Medical Center has received a $31.6 million federal grant to lead a national effort to better understand acute respiratory distress syndrome, pneumonia and sepsis.

By Bill Snyder
Wesley Self, MD, MPH
April 11, 2023

VUMC-led trial shows two investigational drugs are ineffective for treating severe COVID-19

A Vanderbilt-led study evaluating two investigational drugs to treat severe COVID-19 demonstrated that neither drug was effective.

By Nancy Humphrey
March 7, 2023

Treating delirium detected in the ED

Higher intensity physical or occupational therapy may be a useful intervention to shorten delirium duration in older hospitalized adults, Vanderbilt researchers recently reported.

By Leigh MacMillan
February 9, 2023

American Society for Clinical Investigation honors 10 Vanderbilt physicians

By Bill Snyder
Wesley Self, MD, MPH
February 2, 2023

Study of two sepsis interventions finds identical outcomes

Vanderbilt University Medical Center had a leading role in a large national study designed to compare two early interventions in the treatment of patients with sepsis, the body’s severe response to an uncontrolled infection.

By Nancy Humphrey
From left, Sean Collins, MD, MSc, Wesley Self, MD, MPH, Jessica Collins, program director, Vanderbilt Coordinating Center, and Matt Shotwell, PhD, play key roles in a now-international clinical trial platform that is investigating therapies aimed at reducing complications in patients hospitalized with COVID-19.
January 5, 2023

VUMC-led COVID-19 clinical trial platform goes international

The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

By Bill Snyder